Fake drug sales mean fewer people are employed by EU drug firms says EUIPO

By Gareth Macdonald

- Last updated on GMT


Related tags European union Pharmacology Eu

Drug counterfeiting means the EU pharmaceutical industry employs 37,700 fewer people than it otherwise would, according to the European Union Intellectual Property Office (EUIPO). 

New EUIPO research​ suggests counterfeit drugs cost the EU pharmaceutical industry €10.2bn ($11.1bn) a year in lost sales. The organisation believes the drug industry in the European Unuion (EU) employs fewer people as a result.

Those lost sales translate into 37,700 jobs directly lost across the pharmaceutical sector in the EU, as legitimate manufacturers and distributors of pharmaceuticals employ fewer people than they would have done in the absence of counterfeiting​.”

The research, which was conducted in collaboration with the Spanish General Association of Consumers (ASGECO), identified Italy as a hotspot for counterfeit drug sales with around €1.59bn worth of fakes being sold each year.

Fake drug sales in Germany and France cost industry €1bn in lost revenue respective according to the EUIPO. In the UK €605m is lost annually as a result of counterfeiting.

EUIPO Director, António Campinos, said: “We know through analysis done by the World Health Organization (WHO) that both generic and innovator medicines are falsified, from cancer treatment products to inexpensive pain treatments. These fakes can be toxic and pose a serious danger to health.

Our report shows that they also have a serious impact on the economy and on jobs. Our aim is that our data and evidence-based studies will help policymakers as they devise responses to the challenge of combatting fake pharmaceuticals​.”

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more